Core Insights - Ventas reported revenue of $1.24 billion for the quarter ended September 2024, reflecting a 7.5% increase year-over-year and a 2.30% surprise over the Zacks Consensus Estimate of $1.21 billion [1] - The company's EPS was $0.80, a significant improvement from -$0.17 in the same quarter last year, aligning with the consensus estimate [1] Revenue Breakdown - Rental income from triple-net leased properties was $155.35 million, slightly below the estimated $149.95 million, representing a year-over-year decline of 2.8% [3] - Rental income from the outpatient medical & research portfolio reached $220.96 million, exceeding the average estimate of $218.63 million [3] - Total rental income was reported at $376.31 million, surpassing the average estimate of $368.58 million [3] - Resident fees and services generated $845.53 million, exceeding the estimated $830.66 million, marking a year-over-year increase of 12.1% [3] - Third-party capital management revenues were $4.39 million, slightly below the average estimate of $4.57 million [3] - Income from loans and investments was $1.88 million, exceeding the average estimate of $1.48 million, with a year-over-year increase of 55.7% [3] - Interest and other income reached $8.20 million, significantly above the estimated $4.48 million, reflecting a year-over-year increase of 197.9% [3] Earnings Performance - Net Earnings Per Share (Diluted) was reported at $0.05, compared to the average estimate of -$0.02 [3] Stock Performance - Ventas shares have returned +3.4% over the past month, outperforming the Zacks S&P 500 composite's +1.8% change [4] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [4]

Ventas (VTR) came out with quarterly funds from operations (FFO) of $0.80 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.75 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this seniors housing real estate investment trust would post FFO of $0.79 per share when it actually produced FFO of $0.80, delivering a surprise of 1.27%.Over the last four quarters, the company has surpassed consensus FFO estimates two times.V ...

Core Insights - The upcoming earnings report for Ventas (VTR) is anticipated to show quarterly earnings of $0.80 per share, reflecting a 6.7% increase year-over-year, with revenues expected to reach $1.21 billion, a 5.1% increase from the previous year [1] - Analysts have not revised their consensus EPS estimate over the past 30 days, indicating stability in their projections [1][2] - The analysis of earnings estimate revisions is crucial for predicting investor behavior and stock performance [2] Revenue Estimates - Analysts project 'Revenues- Rental income- Triple-net leased' to be $149.95 million, indicating a year-over-year decline of 6.2% [4] - The consensus for 'Revenues- Resident fees and services' is estimated at $830.66 million, which represents a 10.1% increase compared to the same quarter last year [4] Other Key Metrics - The average estimate for 'Depreciation and amortization' is $333.36 million, down from $370.38 million reported in the same quarter last year [5] - Over the past month, Ventas shares have increased by 1.8%, while the Zacks S&P 500 composite has risen by 2% [5] - Ventas currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [5]

Ventas, Inc. (VTR) is scheduled to report third-quarter 2024 results on Oct. 30, after market close. The quarterly results are likely to display year-over-year growth in revenues and normalized funds from operations (FFO) per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.In the last reported quarter, this Chicago-based healthcare real estate investment trust (REIT) delivered a normalized FFO per share of 80 cents, beating the Zacks Consensus Estimate by 1.3%. The quarterly r ...

Core Viewpoint - The article compares two dividend-paying REITs, Ventas and W.P. Carey, highlighting that W.P. Carey is currently the better investment option due to its reliable dividend growth and diversified portfolio, while Ventas has struggled with dividend cuts and has not yet restored its dividend [2][10]. Company Analysis Ventas - Ventas is a healthcare REIT that owns senior housing assets, medical offices, and research facilities, and has a significant portion of its portfolio in senior housing operating assets (SHOPs) [3][4]. - The company faced financial difficulties during the COVID-19 pandemic, leading to a dividend cut due to decreased cash flow from its SHOP portfolio [4][6]. - Although Ventas reported a 7% year-over-year increase in funds from operations (FFO) in Q2 2024, it has not yet resumed dividend payments, raising concerns about its focus on providing reliable income to investors [5][6]. W.P. Carey - W.P. Carey is a net lease REIT that offers a higher dividend yield of 5.6%, compared to Ventas' 2.8% yield, and is known for its diversified portfolio across various sectors including warehouse, industrial, and retail [7][8]. - The company recently exited the office asset segment, which constituted 16% of its portfolio, resulting in a dividend reset; however, it has since resumed increasing its dividend every quarter, signaling a commitment to returning value to shareholders [8][9]. - W.P. Carey is recognized for its management's focus on maintaining and growing dividends, making it a more attractive option for dividend investors compared to Ventas [9][10].

Shares of Ventas (VTR) have gained 48.9% in the past six months compared with the industry's growth of 15.8%. This healthcare real estate investment trust (REIT) is well-positioned to gain from its diverse portfolio of healthcare real estate assets in the key markets of the United States and the U.K. An aging population and the rise in healthcare expenditure by senior citizens are likely to benefit the senior housing operating portfolio (SHOP). The outpatient medical portfolio is expected to gain from favor ...

Ventas (VTR) secured an agreement ("2024 Kindred Agreements") with Kindred Healthcare, LLC and its parent company, ScionHealth. This agreement is regarding 23 long-term acute care hospitals ("LTACs") whose lease term is scheduled to mature on April 30, 2025, under the existing master lease between Ventas and Kindred. This move enhances patient care facilities, strengthens the existing master lease and provide upside for Ventas. The company also obtains rights to additional revenue-sharing rent and warrants. ...

Ventas' (VTR) senior housing operating portfolio (SHOP) is likely to benefit from the aging population and the rising healthcare expenditures by senior citizens. Its outpatient medical and research portfolio is expected to gain from the favorable outpatient visit trends and the rising need for research related to life-saving vaccines and therapeutics. A healthy balance sheet position is likely to support its growth endeavors. However, dependence on few tenants and high interest rates add to its concern. Las ...

Core Viewpoint - Ventas has significantly outperformed the Vanguard Real Estate ETF in 2024, achieving a total return of approximately 22% compared to the ETF's 10% gain, but its elevated valuation suggests a Hold rating is appropriate [2][14] Company Overview - Ventas is a healthcare REIT with 41% of its net operating income (NOI) derived from the Senior Housing Operating Portfolio (SHOP), 31% from the Outpatient Medical & Research Portfolio (OM&R), and 28% from Triple-Net Properties [3] - The company operates a total of 1,345 properties with a gross book value of $32.067 billion and an annual NOI of $2.083 billion [3] Operational Overview - In Q2 2024, Ventas reported a normalized FFO of $0.80 per share, reflecting a 7% year-over-year increase, driven by a 15.2% increase in same-store cash NOI in the SHOP portfolio [4] - The overall same-store cash NOI growth for the company was 7.8%, with modest increases in OM&R and Triple-Net portfolios at 3.3% and 2.6% respectively [4] Increased 2024 Guidance - Following strong Q2 performance, Ventas raised its full-year normalized FFO guidance to approximately $3.15 per share, representing a 5% year-over-year increase [5][6] Capital Structure - As of Q2 2024, Ventas had a net debt of $12.9 billion, with a market capitalization of $24.7 billion, resulting in net debt accounting for 34% of the enterprise value [7] - The weighted average interest rate on the company's debt is 4.3%, with only 9% of the debt at floating rates, limiting benefits from potential monetary policy easing [8] Market-Implied Cap Rate - The market-implied cap rate is approximately 5%, indicating that the strong NOI growth is already reflected in the company's valuation [9] General and Administrative Expenses - The company anticipates general and administrative expenses of about $158 million in 2024, which is relatively low compared to peers, suggesting efficient management [10] Prospects and Valuation - While robust NOI growth is expected to continue, it is anticipated to moderate to low-to-mid single digits due to occupancy limits in the SHOP portfolio [11] - The elevated normalized FFO multiple and limited near-term benefits from Fed rate cuts lead to a Hold rating for Ventas shares [11][14] Covered Call Strategy - To enhance returns, the company suggests a covered call strategy for investors holding Ventas shares, which could provide additional income and mitigate risks during market downturns [12][14]

Shares of Ventas (VTR) have gained 34.1% in the past six months compared with the industry's growth of 7.9%. This Chicago-based healthcare real estate investment trust (REIT) is well-positioned to gain from its diverse portfolio of healthcare real estate assets in the key markets of the United States and the U.K. An aging population and the rise in healthcare expenditure by senior citizens are likely to benefit the senior housing operating portfolio (SHOP). The outpatient medical portfolio is expected to ga ...